zentalis.com

Provided by Alexa ranking, zentalis.com has ranked N/A in N/A and N/A on the world. It is hoted in N/A with IP address 99.83.190.102. The home page has 0 external link.

Category: Aviation

Top keyword related from Search Engine of zentalis.com

Traffic Ranks of zentalis.com

Owner:	N/A
RANK:	N/A
Country code:	N/A
Country name:	N/A
Rank on country:	N/A
Host:	N/A
Ip:	99.83.190.102
Ref link:
Extension:	com

Top URL related to zentalis.com

• 1. Zentalis Pharmaceuticals

  zentalis.com

  Link: https://www.zentalis.com/

  Description: WEBAbout Zentalis. Improving Patient lives. We are a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. Learn More.

• 2. About Us - Zentalis Pharmaceuticals

  zentalis.com

  Link: https://www.zentalis.com/about/company

  Description: WEBNYU Langone Health. Learn about Zentalis, an innovative oncology company focused on developing transformative cancer treatments, driven by cutting-edge research and a patient-centric approach.

• 3. Pipeline - Zentalis Pharmaceuticals

  zentalis.com

  Link: https://www.zentalis.com/pipeline/pipeline

  Description: WEBExplore Zentalis' robust pipeline of next-generation cancer therapies targeting difficult-to-treat cancers. Azenosertib is a potentially first-in-class and best-in-class oral WEE1 inhibitor in development for the treatment of advanced solid tumors. Discover our innovative approach to revolutionizing cancer care.

• 4. Zentalis Pharmaceuticals Announces Updates Across its Pipeline

  zentalis.com

  Link: https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-announces-updates-across-its-pipeline/

  Description: WEBZentalis is planning to launch a biomarker-driven Phase 2 study pending FDA feedback. The tumor-agnostic trial will investigate ZN-c3 in patients with solid tumors that express the identified predictive biomarker, and is expected to initiate by year-end.

• 5. Press Releases | Zentalis Pharmaceuticals

  zentalis.com

  Link: https://ir.zentalis.com/news-events/press-releases

  Description: WEBApr 02, 2024. Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024. Apr 01, 2024.

• 6. Zentalis Pharmaceuticals Announces Positive Initial Clinical Data …

  zentalis.com

  Link: https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-announces-positive-initial-clinical

  Description: WEBNEW YORK and SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced initial efficacy and safety data from the ongoing Phase 1b ...

• 7. Investors/Media Home | Zentalis Pharmaceuticals

  zentalis.com

  Link: https://ir.zentalis.com/

  Description: WEBZentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer. Recent News. Learn More.

• 8. Zentalis Pharmaceuticals Announces First Patient Dosed in …

  zentalis.com

  Link: https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-announces-first-patient-dosed/

  Description: WEBNEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the first patient has been dosed in the Phase 2 trial of ...

• 9. Zentalis Pharmaceuticals Enters into Clinical Collaboration and …

  zentalis.com

  Link: https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-enters-clinical-collaboration-and/

  Description: WEBApr 12, 2021 · Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor | Zentalis Pharmaceuticals. Skip to main navigation. . About Us. Our Company.

• 10. Zentalis Pharmaceuticals | LinkedIn

  linkedin.com

  Link: https://www.linkedin.com/company/zentalis-pharmaceuticals/

  Description: WEBZentalis Pharmaceuticals | LinkedIn. Biotechnology Research. New York, NY 15,765 followers. Developing small molecule therapeutics targeting fundamental biological pathways of cancers. View all...